Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL4I1 | Q96RQ9 | 7/20 | 0.74 |
| ▸ | ACKR3 | P25106 | 7/20 | 0.43 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30948141 | 0.98 | IL4I1 (0.70) | IL4I1ACKR3SCD5MAPTRECQL | |
| SCHEMBL30948255 | 0.85 | IL4I1 (1.00) | IL4I1SCD5HSD17B13NPC1RAB9A | |
| SCHEMBL30948289 | 0.83 | IL4I1 (0.80) | IL4I1ACKR3MAPTHSD17B13NPC1 | |
| SCHEMBL30948077 | 0.82 | IL4I1 (0.79) | IL4I1SCD5HSD17B13 | |
| SCHEMBL30948066 | 0.82 | IL4I1 (0.71) | IL4I1ACKR3MAPTRECQLCYP3A4 | |
| SCHEMBL30948133 | 0.81 | IL4I1 (0.74) | IL4I1SCD5MAPTNPC1RAB9A | |
| SCHEMBL30948142 | 0.80 | IL4I1 (0.74) | IL4I1ACKR3MAPTRECQLCYP3A4 | |
| SCHEMBL30948097 | 0.80 | IL4I1 (0.70) | IL4I1MAPTKCNH2 | |
| SCHEMBL30948047 | 0.79 | IL4I1 (0.74) | IL4I1 | |
| SCHEMBL30948216 | 0.78 | IL4I1 (0.67) | IL4I1HSD17B13NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | IL4I1 1/4885ACKR3 1843/4885SCD5 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.